Partial Nephrectomy for Renal Cancer: Part I
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Risk of Tumour Recurrence in Patients Undergoing Renal
The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review Romain Boissier, Vital Hevia, Harman Max Bruins, Klemens Budde, Arnaldo Figueiredo, Enrique Lledó-García, Jonathon Olsburgh, Heinz Regele, Claire Fraser Taylor, Rhana Hassan Zakri, et al. To cite this version: Romain Boissier, Vital Hevia, Harman Max Bruins, Klemens Budde, Arnaldo Figueiredo, et al.. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. European Urology, Elsevier, 2018, pp.94 - 108. 10.1016/j.eururo.2017.07.017. hal-01792732 HAL Id: hal-01792732 https://hal-amu.archives-ouvertes.fr/hal-01792732 Submitted on 18 May 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 The risk of tumour recurrence in patients undergoing renal transplantation for end- stage renal disease after previous treatment for a urological cancer: a systematic review Romain Boissier1*, Vital Hevia2*, Harman Max Bruins3, Klemens Budde4, Arnaldo Figueiredo5, Enrique Lledó García6, Jonathon Olsburgh7, Heinz Regele8, Claire Fraser Taylor9, Rhana Hassan Zakri7, Cathy Yuhong Yuan10 and Alberto Breda11 * These authors contributed equally and share the first authorship 1. -
Wilms Tumour (Nephroblastoma) – Brief Information
Wilms Tumour (Nephroblastoma) – Brief information Copyright © 2017 Competence Network Paediatric Oncology and Haematology Author: Maria Yiallouros, created 2009/02/12, Editor: Maria Yiallouros, Release: Prof. Dr. med. Norbert Graf, English Translation: Dr. med. habil. Gesche Tallen, Last modified: 2017/06/27 Kinderkrebsinfo is sponsored by Deutsche Kinderkrebsstiftung Wilms Tumour (Nephroblastoma) – Brief information Page 2 Table of Content 1. General information on the disease ................................................................................... 3 2. Incidence .......................................................................................................................... 3 3. Causes ............................................................................................................................. 4 4. Symptoms ........................................................................................................................ 4 5. Diagnosis ......................................................................................................................... 4 5.1. Diagnostic imaging ....................................................................................................... 5 5.2. More tests to confirm diagnosis and to assess tumour spread (metastases) ..................... 5 5.3. Tests for preparing the treatment ................................................................................... 5 5.4. Obtaining a tumour sample (biopsy) ............................................................................. -
Wilms' Tumour (Nephroblastoma)
Wilms’ tumour (nephroblastoma) Wilms’ tumour is generally found only in children and very rarely in adults. JANET E POOLE, MB BCh, DCH (SA), FCP (SA) Paed Professor, Department of Paediatrics, Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand, Johannesburg Janet Poole qualified as a medical doctor in 1978 at the University of the Witwatersrand and became a specialist paediatrician in 1983. She commenced work in the Paediatric Haematology/Oncology Unit at the Johannesburg Hospital in 1984 and has 25 years’ experience in that field. She was head of the Chris Hani Baragwanath Paediatric Haematology/Oncology Unit from 1989 to 1997, after which she became head of the Unit at Johannesburg Hospital. Her special interests are childhood leukaemia, Wilms’ tumour, and inherited haemoglobin defects. She has been involved with CHOC (a parent support group) since starting work in the unit. Correspondence to: J Poole ([email protected]) a bleeding diathesis, polycythaemia, weight loss, urinary infection, Epidemiology diarrhoea or constipation. Wilms’ tumour or nephroblastoma is a cancer of the kidney that The differential diagnosis of a renal mass includes hydronephrosis, typically occurs in children and very rarely in adults. The common polycystic kidney disease and infrequently xanthogranulomatous name is an eponym, referring to Dr Max Wilms, the German pyelonephritis. Non-renal peritoneal masses include neuroblastoma surgeon who first described this type of tumour in 1899. Wilms’ and teratoma (Fig. 1). tumour is the most common form of kidney cancer in children and is also known as nephroblastoma. Nephro means kidney, and a blastoma is a tumour of embryonic tissue that has not yet fully developed. -
Urogenital System Surgery Urogenital System Anatomy
UROGENITAL SYSTEM SURGERY UROGENITAL SYSTEM ANATOMY Kidneys and Ureters Urinary Bladder Urethra Genital Organs Male Genital Organs Female KIDNEY and URETHERS The kidneys lie in the retroperitoneal space lateral to the aorta and the caudal vena cava. They have a fibrous capsule and are held in position by subperitoneal connective tissue. The renal pelvis is the funnel shaped structure that receives urine and directs it into the ureter. Generally, five or six diverticula curve outward from the renal pelvis. The renal artery normally bifurcates into dorsal and ventral branches; however, variations in the renal arteries and veins are common. The ureter begins at the renal pelvis and enters the dorsal surface of the bladder obliquely by means of two slit like orifices. The blood supply to the ureter is provided from the cranial ureteral artery (from the renal artery) and the caudal ureteral artery (from the prostatic or vaginal artery). Urinary bladder and urethra The bladder is divided into the trigone, which connects it to the urethra, and the body. The urethra in male dogs and cats is divided into prostatic, membranous (pelvic), and penile portions. Surgery of Kidney and Urethers Nephrectomy is excision of the kidney; nephrotomy is a surgical incision into the kidney. Pyelolithotomy is an incision into the renal pelvis and proximal ureter; a ureterotomy is an incision into the ureter; both are generally used to remove calculi. Neoureterostomy is a surgical procedure performed to correct intramural ectopic ureters; ureteroneocystostomy involves implantation of a resected ureter into the bladder. Nephrotomy to obtain tissue samples or to gain access to the renal pelvis for removal of nephroliths or other obstructive lesions. -
(Pro)Renin Receptor (PRR) Expression in Renal Tumours
diagnostics Article Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours Jon Danel Solano-Iturri 1,2,3, Enrique Echevarría 4, Miguel Unda 5, Ana Loizaga-Iriarte 5, Amparo Pérez-Fernández 5, Javier C. Angulo 6, José I. López 3,7 and Gorka Larrinaga 3,4,8,* 1 Department of Pathology, Donostia University Hospital, 20014 Donostia/San Sebastian, Spain; [email protected] 2 Department of Medical-Surgical Specialities, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain 3 Biocruces-Bizkaia Health Research Institute, 48903 Barakaldo, Spain; [email protected] 4 Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; [email protected] 5 Department of Urology, Basurto University Hospital, University of the Basque Country (UPV/EHU), 48013 Bilbao, Spain; [email protected] (M.U.); [email protected] (A.L.-I.); [email protected] (A.P.-F.) 6 Clinical Department. Faculty of Medical Sciences. European University of Madrid, 28905 Getafe, Spain; [email protected] 7 Department of Pathology, Cruces University Hospital, 48903 Barakaldo, Spain 8 Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain * Correspondence: [email protected] Citation: Solano-Iturri, J.D.; Abstract: (1) Background: Renal cancer is one of the most frequent malignancies in Western countries, Echevarría, E.; Unda, M.; with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of Loizaga-Iriarte, A.; Pérez-Fernández, reliable biomarkers of tumour progression. -
Methods of Urolith Removal
3 CE CE Article CREDITS Methods of Urolith Removal Cathy Langston, DVM, DACVIM (Small Animal Internal Medicine) Kelly Gisselman, DVM Douglas Palma, DVM John McCue, DVM Animal Medical Center New York, New York Abstract: Multiple techniques exist to remove uroliths from each section of the urinary tract. Minimally invasive methods for removing lower urinary tract stones include voiding urohydropropulsion, retrograde urohydropropulsion followed by dissolution or removal, catheter retrieval, cystoscopic removal, and cystoscopy-assisted laser lithotripsy and surgery. Laparoscopic cysto- tomy is less invasive than surgical cystotomy. Extracorporeal shock wave lithotripsy can be used for nephroliths and ureteroliths. Nephrotomy, pyelotomy, or urethrotomy may be recommended in certain situations. This article discusses each technique and gives guidance for selecting the most appropriate technique for an individual patient. ew, minimally invasive techniques for removing preventive measures.7 Surgical removal of partial or com- uroliths have been developed or have become more pletely obstructing ureteroliths that do not pass within 24 Nreadily available in veterinary medicine. TABLE hours may be prudent.8 A staged approach to surgery can be 1 summarizes the advantages and disadvantages of each considered if uroliths are found at multiple sites in the upper method, the number and type of uroliths for which each is urinary tract. The reversibility of renal dysfunction depends appropriate, and necessary equipment for each. on completeness and duration -
Approaches to Pyelolithotomy
Vet Times The website for the veterinary profession https://www.vettimes.co.uk APPROACHES TO PYELOLITHOTOMY Author : Nitzan Kroter Categories : Vets Date : February 14, 2011 Nitzan Kroter discusses this procedure in reference to a case involving the removal of calcium phosphate renoliths in a cat with only one functional kidney Summary A 12-year-old cat was presented for chronic weight loss. Clinical evaluation and investigation revealed an atrophied left kidney with nephroliths and an enlarged right kidney containing multiple renal calculi. Bilateral calcium phosphate renal calculi were diagnosed. This report describes pyelolithotomy in a cat. Pyelolithotomy was performed to avoid damage to the renal parenchyma, which could occur during a nephrotomy, and, therefore, minimise further damage to an already compromised kidney. Before performing surgery, consideration of the patient’s renal function is important to obtain optimal results. Maintaining normal urine production in the pre-operative and postoperative period is important in all cases. Pyelolithotomy in the dog is covered and described in the literature; the author is unaware of a detailed description of pyelolithotomy in a cat. Key words kidney, pyelolithotomy, urine 1 / 7 A NEUTERED domestic shorthaired male feline presented with a complaint of marked weight loss over the preceding few months. It weighed 2.6kg. When recorded two-and-ahalf years previously, its weight had been 5.5kg. The owner reported recent increased activity, the cat was more talkative and attention seeking, and had a normal appetite. There was no history of polydipsia or polyuria, and there had been no vomiting or diarrhoea. Clinical examination and investigation The patient had a body condition score of 2/4 and an unkempt coat, but it was responsive and alert. -
New Alternatives for Minimally Invasive Management of Uroliths: Nephroliths
3 CE Credits New Alternatives for Minimally Invasive Management of Uroliths: Nephroliths Alice Defarges, DVM, DACVIM University of Guelph Allyson Berent, DVM, DACVIM The Animal Medical Center New York, New York Marilyn Dunn, DMV, DACVIM Université de Montreal Abstract: Urolithiasis is a common clinical problem in small animal veterinary patients. Management of upper urinary tract calculi can be particularly challenging in small animals, as traditional surgical removal can be associated with significant morbidity. In humans, minimally invasive treatment options have replaced traditional surgical removal in many cases. This article reviews the current literature on the various types of lithotripsy and some of the newer minimally invasive options available for management of nephrolithiasis in small animal veterinary patients. An article in the January 2013 issue addressed management of lower urinary tract uroliths; a future article will discuss current management strategies for ureteroliths. For more information, please see the companion article: Nephrolithiasis “New Alternatives for Minimally Invasive Management of Uroliths: Many canine and feline nephroliths remain static in size and Lower Urinary Tract Uroliths” (January 2013). clinically silent for years. Some controversy still exists as to whether nonobstructive kidney stones worsen underlying kidney disease.5 rolithiasis is a common clinical problem in small animal Removal of these stones is typically recommended if the stones veterinary patients. In the past, nephroliths were treated -
Neoplastic Metastases to the Endocrine Glands
27 1 Endocrine-Related A Angelousi et al. Metastases to endocrine 27:1 R1–R20 Cancer organs REVIEW Neoplastic metastases to the endocrine glands Anna Angelousi1, Krystallenia I Alexandraki2, George Kyriakopoulos3, Marina Tsoli2, Dimitrios Thomas2, Gregory Kaltsas2 and Ashley Grossman4,5,6 1Endocrine Unit, 1st Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece 2Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece 3Department of Pathology, General Hospital ‘Evangelismos’, Αthens, Greece 4Department of Endocrinology, OCDEM, University of Oxford, Oxford, UK 5Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK 6Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK Correspondence should be addressed to A Angelousi: [email protected] Abstract Endocrine organs are metastatic targets for several primary cancers, either through Key Words direct extension from nearby tumour cells or dissemination via the venous, arterial and f glands lymphatic routes. Although any endocrine tissue can be affected, most clinically relevant f cancer metastases involve the pituitary and adrenal glands with the commonest manifestations f metastases being diabetes insipidus and adrenal insufficiency respectively. The most common f pituitary primary tumours metastasing to the adrenals include melanomas, breast and lung f adrenal carcinomas, which may lead to adrenal insufficiency in the presence of bilateral adrenal f thyroid involvement. Breast and lung cancers are the most common primaries metastasing to f ovaries the pituitary, leading to pituitary dysfunction in approximately 30% of cases. The thyroid gland can be affected by renal, colorectal, lung and breast carcinomas, and melanomas, but has rarely been associated with thyroid dysfunction. -
Tnm Frequently Asked Questions (Faq’S)
TNM FREQUENTLY ASKED QUESTIONS (FAQ’S) The TNM Project Committee receives questions concerning the use of TNM and how to interpret rules in specific situations. Some questions and answers are listed below by category for your convenience. These FAQs can th also be found in the TNM Supplement: a Commentary on Uniform Use, 4 Edition, 2012 (edited by Ch. Wittekind, C. Compton, J. Brierley, L. H. Sobin). Advice on further questions may be obtained from the TNM Helpdesk by accessing the TNM Classification of Malignant Tumours page at the UICC website www.uicc.org TABLE OF CONTENTS GENERAL QUESTIONS AJCC versus UICC TNM ................................................................................................................3 In situ carcinoma .............................................................................................................................3 Pathological Versus Clinical TNM ...................................................................................................3 When in Doubt ................................................................................................................................4 R Classification ...............................................................................................................................4 R Classification and Tis ..................................................................................................................5 Positive Cytology ............................................................................................................................5 -
Book of Courage and Hope
BOOK Kidney Cancer Patient Stories From Around OF The World COURAGE AND HOPE Introduction Thank you to the kidney cancer patients, Around the world, kidney cancer patients The IKCC “Book of Courage and Hope” also caregivers, and families who are featured so share a wide range of challenges – not only illustrates our belief that being a part of a beautifully throughout this “Book of Courage with different subtypes and stages of disease, cancer patient support group and sharing and Hope”. Sharing personal stories takes but often with inequitable and complex knowledge and experiences with each other tremendous courage. Each story is an amaz health systems in their home countries. The not only helps individual patients, but can ing testimony to the courage and unique determination of individual patients to push also serve more broadly to increase challenges faced by kidney cancer patients for better treatment options, to demand know ledge of unmet medical needs, raise and their caregivers. better care and support their fellow patients awareness, and foster further research in is truly remarkable. On behalf of the Inter kidney cancer. national Kidney Cancer Coalition (IKCC), we owe these patients and their families our deepest gratitude. 2 If there is an underlying theme that runs By publishing this book, the IKCC hopes to We welcome your feedback through most of our patient stories, it is one demonstrate the breadth and diversity of the on this publication: of fellowship and an innate understanding global kidney cancer community and, along [email protected] that it is often patients who are best motiva with our Affiliate Organisations, our shared Dr. -
Kidney Cancer
Cancer Association of South Africa (CANSA) Fact Sheet on Kidney Cancer Introduction The kidneys are two organs that serve several essential regulatory roles in man. They form an essential part of the urinary system and also serve homeostatic functions such as the regulation of electrolytes, maintenance of acid–base balance and regulation of blood pressure (by maintaining salt and water balance). They serve the body as a natural filter of the blood and remove wastes which are diverted to the urinary bladder. In the process of producing urine, the kidneys excrete wastes such as urea and ammonia. They are also responsible for the reabsorption of water, glucose, and amino acids. The kidneys also produce hormones including calcitriol, erythropoietin, and the enzyme renin. [Picture Credit: Urinary Tract Anatomy]. Bergerot, C.D., Battle, D., Bergerot, P.G., Dizman, N., Jonasch, E., Hammers, H.J., George, D.J., Bex, A., Ljungberg, B., Pal, S.K. & Staehler, M.D. 2019. “Despite numerous therapeutic advances in renal cell carcinoma (RCC), little is known about patients' perspectives on cancer care. An international survey was conducted to identify points of frustration associated with cancer care reported by patients with RCC. Data were obtained from an online survey, conducted from April 1 to June 15, 2017, through social media and patient networking platforms. This survey obtained baseline demographic, clinicopathologic, and treatment-related information. Open-ended questions accessed sources of frustration in cancer-related care and patients' suggestions for amelioration. Responses were categorized and reviewed by independent reviewers. A qualitative analysis was performed and the Kruskal-Wallis test was used to define associations between baseline characteristics and sources of frustration.